Viridian Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Business Progress
Business Wire•04/11/2026•07:01 ET
0
Key Highlights
- ➤Lumvoa generated $24.7 million net product revenue in Q3 2026
- ➤More than 100 patients were on Lumvoa therapy at Q3 end
- ➤Cash, cash equivalents, and marketable securities totaled $955.2 million
- ➤Elegrobart BLA submission remains on track for Q1 2027
- ➤Net loss widened to $101.2 million from $34.6 million year over year
Expert Statements
Steve Mahoney, President and Chief Executive Officer of Viridian Therapeutics
“We are highly encouraged by the strength of Lumvoa's early launch in TED, which has exceeded expectations”
Steve Mahoney, President and Chief Executive Officer of Viridian Therapeutics
“These strong early results are a testament to Lumvoa's compelling clinical profile, the extraordinary execution of our Commercial and Medical teams, and the incredible support of our broader organization.”
Steve Mahoney, President and Chief Executive Officer of Viridian Therapeutics
“We are excited about this early momentum and look forward to building on it as we continue to execute our launch strategy and strive to bring Lumvoa to more patients with TED.”
Steve Mahoney, President and Chief Executive Officer of Viridian Therapeutics
“Our pipeline also continues to move forward as we advance elegrobart, our subcutaneously administered anti-IGF-1R, toward a planned BLA submission for TED in the first quarter of 2027.”
Steve Mahoney, President and Chief Executive Officer of Viridian Therapeutics
“In addition, we look forward to several important milestones for the remainder of this year, including sharing clinical data for VRDN-008, development plans for our FcRn portfolio, and initiating a first-in-human clinical trial in patients for our TSHR program VRDN-292.”
Viridian Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Business Progress
- $24.7 million in Lumvoa™ (veligrotug-vvze) net product revenue with more than 100 patients on therapy at the end of Q3 2026 -
Get started
Create a free account to read the full story.